Using remote ischemic preconditioning to prevent kidney injury in septic patients
Effect of Remote Ischemic Preconditioning in Septic Patients on Cell Cycle Arrest Biomarkers - the RIPC-ICU Randomized Clinical Trial
This study is testing if a special technique that temporarily restricts blood flow in the arm can help prevent kidney injury in critically ill patients with sepsis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität Münster Academic / other |
| Locations | 1 site (Münster) |
| Trial ID | NCT05830669 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of remote ischemic preconditioning (RIPC) to reduce the incidence of acute kidney injury (AKI) in critically ill patients suffering from sepsis. The approach involves inducing ischemia in the upper limb through three cycles, which is hypothesized to provide protective effects on the kidneys. The effectiveness of RIPC will be assessed using urinary biomarkers such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7). The trial aims to establish a clinically viable method to mitigate AKI in this vulnerable patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older who are critically ill with sepsis and require invasive ventilation or vasopressor therapy.
Not a fit: Patients with pre-existing acute kidney injury, chronic kidney disease, or those on chronic dialysis are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence and severity of acute kidney injury in critically ill septic patients.
How similar studies have performed: While the concept of remote ischemic preconditioning has been explored in various contexts, this specific application in septic patients with acute kidney injury is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with sepsis \< 12 hours * Invasive ventilation for at least 24 hours (propofol-free-sedation) and/or vasopressor therapy * Unrestricted intensive care for at least 72 hours * Written informed consent Exclusion Criteria: * Pre-existing AKI * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Chronic dialysis dependency * Kidney transplant in the last 12 months * Oral antidiabetics, sulfonamides or nicorandil * Pregnancy or breastfeeding * Do-not-reanimate order * Participation in another interventional trial involving kidney outcomes within the last 3 months * Dependency on the investigator or center
Where this trial is running
Münster
- University Hospital Münster; Department of Anesthesiology, Intensive Care Medicine and Pain Medicine — Münster, Germany (Recruiting)
Study contacts
- Principal investigator: Melanie Meersch-Dini, MD — University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine
- Study coordinator: Melanie Meersch-Dini, MD
- Email: meersch@uni-muenster.de
- Phone: +49-251-8347255
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.